If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access
Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India
Subscribe To Our Newsletter & Stay Updated
